(Q35159582)

6 August 2017

1 reference

title

Development of a vaccine for the prevention of AIDS, a critical appraisal (English)

1 reference

6 August 2017

main subject

prevention of HIV/AIDS

1 reference

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

22 November 2023

2

Bolognesi DP

1 reference

6 August 2017

D. T. Karzon

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1281948

8 September 2022

D. P. Bolognesi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1281948

8 September 2022

W. C. Koff

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1281948

8 September 2022

language of work or name

English

0 references

publication date

1 January 1992

1 reference

full work available at URL

6 August 2017

number of pages

14

1 reference

based on heuristic

inferred from page(s)

https://api.elsevier.com/content/article/PII:0264410X9290114Y?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

https://api.elsevier.com/content/article/PII:0264410X9290114Y?httpAccept=text/plain

22 November 2023

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

22 November 2023

1 reference

6 August 2017

volume

10

1 reference

6 August 2017

issue

14

1 reference

6 August 2017

page(s)

1039-1052

1 reference

The immunological principles of vaccination

6 August 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants

22 November 2023

3

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion

22 November 2023

4

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Isolation of human immunodeficiency virus (HIV) from plasma during primary HIV infection

22 November 2023

5

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection

22 November 2023

6

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Transient High Levels of Viremia in Patients with Primary Human Immunodeficiency Virus Type 1 Infection

22 November 2023

7

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Isolate-specific neutralizing antibodies in patients with progressive HIV-1-related disease

22 November 2023

8

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody

22 November 2023

9

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Prevention of HIV infection by passive immunization with HIV immunoglobulin

22 November 2023

10

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients

22 November 2023

11

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene.

22 November 2023

12

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus

22 November 2023

14

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV

22 November 2023

15

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule

22 November 2023

16

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein.

22 November 2023

17

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1

22 November 2023

18

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane

22 November 2023

19

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

The role of the V3 loop of gp120 in HIV infection.

22 November 2023

21

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1.

22 November 2023

22

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.

22 November 2023

23

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody

22 November 2023

24

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody

22 November 2023

25

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Evidence for the direct involvement of the rhinovirus canyon in receptor binding

22 November 2023

26

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Neutralization of Divergent HIV-1 Isolates by Conformation-Dependent Human Antibodies to Gp120

22 November 2023

27

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans

22 November 2023

28

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains

22 November 2023

29

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120

22 November 2023

30

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells

22 November 2023

32

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

HIV susceptibility conferred to human fibroblasts by cytomegalovirus-induced Fc receptor

22 November 2023

33

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Peptide component vaccine engineering: targeting the AIDS virus

22 November 2023

34

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

HIV epitopes recognized by cytotoxic T-lymphocytes

22 November 2023

35

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition

22 November 2023

36

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

A single amino acid interchange yields reciprocal CTL specificities for HIV-1 gp160

22 November 2023

37

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

22 November 2023

Anti-HIV-1 ADCC.

38

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

The mucosal immune system: from fundamental concepts to vaccine development

22 November 2023

39

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Inactivated simian immunodeficiency virus vaccine failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously exposed animals

22 November 2023

41

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

SIV vaccines, 1991—a year in review

22 November 2023

42

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160.

22 November 2023

43

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Helper independent recombinant adenovirus vectors: expression of HIV env or HBV surface antigen

22 November 2023

46

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Live Salmonella as vaccines and carriers of foreign antigenic determinants

22 November 2023

47

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Humoral and cell-mediated immune responses to live recombinant BCG–HIV vaccines

22 November 2023

48

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

HIV-1 neutralization directed to epitopes other than linear V3 determinants

22 November 2023

49

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Identification of homologous regions in human immunodeficiency virus I gp41 and human MHC class II beta 1 domain. I. Monoclonal antibodies against the gp41-derived peptide and patients' sera react with native HLA class II antigens, suggesting a role

22 November 2023

50

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus

22 November 2023

51

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen

22 November 2023

53

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Current status of immunological adjuvants

22 November 2023

55

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine

22 November 2023

56

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

The expression of hybrid HIV:Ty virus-like particles in yeast

22 November 2023

57

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Liposomes as immunological adjuvants: antigen incorporation studies

22 November 2023

58

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs

22 November 2023

59

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Biodegradable microspheres as a vaccine delivery system

22 November 2023

62

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Discussion paper: the use of primates in experimental viral infections--rubella and the rubella syndrome

22 November 2023

67

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Progress with HIV vaccines

22 November 2023

72

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function

22 November 2023

73

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Transfer of a functional human immune system to mice with severe combined immunodeficiency

22 November 2023

74

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.

22 November 2023

75

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Anti-cell antibody in macaques

22 November 2023

76

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network

22 November 2023

77

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Immunization of chimpanzees with the HIV-1 glycoprotein gp160 induces long-lasting T-cell memory

22 November 2023

78

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine.

22 November 2023

79

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons

22 November 2023

80

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.

22 November 2023

81

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein

22 November 2023

82

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Neutralization of HTLV-III/LAV replication by antiserum to thymosin alpha 1.

22 November 2023

83

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping

22 November 2023

84

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

HIV p24-specific helper T cell clones from immunized primates recognize highly conserved regions of HIV-1

22 November 2023

85

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

A novel method for the purification of HIV-1 p24 protein from hybrid Ty virus-like particles (Ty-VLPs).

22 November 2023

86

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network

22 November 2023

87

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Immunization against AIDS in humans

22 November 2023

88

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS.

22 November 2023

89

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Antibody-dependent enhancement of human immunodeficiency virus type 1 infection

22 November 2023

90

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry

22 November 2023

91

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Human trials of AIDS vaccines: current status and future directions

22 November 2023

92

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

The emergence of simian/human immunodeficiency viruses

22 November 2023

96

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

Development and testing of AIDS vaccines

22 November 2023

98

1 reference

https://api.crossref.org/works/10.1016/0264-410X(92)90114-Y

22 November 2023

Identifiers

1 reference

6 August 2017

1 reference